ASX:IMC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Immuron's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IMC is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: IMC's weekly volatility has decreased from 54% to 14% over the past year, but is still higher than 75% of Australian stocks.


Market Performance


7 Day Return

-3.8%

IMC

-2.9%

AU Biotechs

1.3%

AU Market


1 Year Return

78.6%

IMC

7.4%

AU Biotechs

-1.7%

AU Market

Return vs Industry: IMC exceeded the Australian Biotechs industry which returned 7.4% over the past year.

Return vs Market: IMC exceeded the Australian Market which returned -1.7% over the past year.


Shareholder returns

IMCIndustryMarket
7 Day-3.8%-2.9%1.3%
30 Day0%4.8%10.4%
90 Day-24.2%4.3%8.8%
1 Year78.6%78.6%8.4%7.4%1.7%-1.7%
3 Year38.9%38.9%116.4%109.3%23.1%7.9%
5 Year-44.6%-45.1%220.2%201.0%57.2%26.0%

Long-Term Price Volatility Vs. Market

How volatile is Immuron's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Immuron undervalued compared to its fair value and its price relative to the market?

7.9x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IMC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IMC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IMC is unprofitable, so we can't compare its PE Ratio to the XX Biotechs industry average.

PE vs Market: IMC is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMC is overvalued based on its PB Ratio (7.9x) compared to the AU Biotechs industry average (6.4x).


Next Steps

Future Growth

How is Immuron forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immuron has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Immuron performed over the past 5 years?

6.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IMC is currently unprofitable.

Growing Profit Margin: IMC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMC is unprofitable, but has reduced losses over the past 5 years at a rate of 6.8% per year.

Accelerating Growth: Unable to compare IMC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (9%).


Return on Equity

High ROE: IMC has a negative Return on Equity (-51.86%), as it is currently unprofitable.


Next Steps

Financial Health

How is Immuron's financial position?


Financial Position Analysis

Short Term Liabilities: IMC's short term assets (A$4.4M) exceed its short term liabilities (A$516.4K).

Long Term Liabilities: IMC's short term assets (A$4.4M) exceed its long term liabilities (A$41.8K).


Debt to Equity History and Analysis

Debt Level: IMC is debt free.

Reducing Debt: IMC has no debt compared to 5 years ago when its debt to equity ratio was 0.5%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IMC is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Immuron current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.5yrs

Average board tenure


CEO

Jerry Kanellos (59 yo)

0.67

Tenure

AU$244,538

Compensation

Dr. Jerry Kanellos, Ph.D has been Chief Executive Officer of Immuron Limited since March 25, 2020 and is its Chief Operating Officer since July 2015. Dr. Kanellos served as Interim Chief Executive Officer ...


CEO Compensation Analysis

Compensation vs Market: Jerry's total compensation ($USD180.78K) is below average for companies of similar size in the Australian market ($USD282.32K).

Compensation vs Earnings: Jerry's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Peter Anastasiou
Executive Vice Chairman5.5yrsAU$50.00k0.80%
A$ 453.8k
Roger Aston
Independent Non-Executive Chairman8.67yrsAU$76.65k0.67%
A$ 380.1k
Arun Sanyal
Member of Advisory Boardno datano datano data
Daniel Pollock
Independent Non-Executive Director8.08yrsAU$65.70k0.38%
A$ 217.0k
Stephen Anastasiou
Independent Non-Executive Director7.5yrsAU$50.00k1.58%
A$ 893.5k
Stephen Harrison
Member of Advisory Boardno datano datano data
Gerhard Rogler
Member of Advisory Boardno datano datano data
Manal Abdelmalek
Member of Advisory Boardno datano datano data
Miriam Vos
Member of Advisory Boardno datano datano data
Dena Lyras
Member of Advisory Boardno datano datano data
Ravi Savarirayan
Independent Non-Executive Director3.58yrsAU$50.00k0.79%
A$ 450.0k

7.5yrs

Average Tenure

60yo

Average Age

Experienced Board: IMC's board of directors are considered experienced (7.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IMC insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28%.


Top Shareholders

Company Information

Immuron Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Immuron Limited
  • Ticker: IMC
  • Exchange: ASX
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$56.709m
  • Shares outstanding: 226.84m
  • Website: https://www.immuron.com.au

Number of Employees


Location

  • Immuron Limited
  • 62 Lygon Street
  • Level 3
  • Carlton
  • Victoria
  • 3053
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMCASX (Australian Securities Exchange)YesOrdinary SharesAUAUDApr 1999
IMCCHIA (Chi-X Australia)YesOrdinary SharesAUAUDApr 1999
ANWDB (Deutsche Boerse AG)YesOrdinary SharesDEEURApr 1999
IMRNNasdaqCM (Nasdaq Capital Market)SPONSORED ADRUSUSDJan 2008
ANWADB (Deutsche Boerse AG)SPONSORED ADRDEEURJan 2008

Biography

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/29 07:03
End of Day Share Price2020/11/27 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.